What is the clinical significance of a plasma ADAMTS13 activity result less than 5%?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ADAMTS13 Activity <5%: Critical Diagnostic Finding for Thrombotic Thrombocytopenic Purpura

An ADAMTS13 activity level <5% is diagnostic for thrombotic thrombocytopenic purpura (TTP) in the appropriate clinical context and represents a medical emergency requiring immediate treatment initiation to prevent mortality from microvascular thrombosis and multi-organ ischemic damage. 1

Immediate Clinical Significance

A value <5% indicates severe ADAMTS13 deficiency, which is the pathophysiological hallmark of TTP. This severe deficiency prevents the normal cleavage of ultra-large von Willebrand factor (UL-VWF) multimers, leading to:

  • Excessive platelet adhesion and aggregation throughout the microcirculation
  • Widespread microvascular thrombus formation causing ischemic organ damage
  • Potential mortality if untreated—historically nearly 100% fatal, now >95% survival with appropriate treatment 2

Diagnostic Algorithm

When ADAMTS13 activity returns <5%, proceed as follows:

1. Confirm Clinical Context

Look for the characteristic pentad (though not all need be present):

  • Severe thrombocytopenia (typically <30 × 10⁹/L) 1
  • Microangiopathic hemolytic anemia with schistocytes, elevated LDH, low hemoglobin/hematocrit
  • Neurological symptoms (confusion, stroke, seizures)
  • Renal impairment (though often milder in severe ADAMTS13 deficiency) 3
  • Fever

Critical caveat: Do not wait for all five features—TTP can present with thrombocytopenia and hemolytic anemia alone. The diagnosis should be considered with ADAMTS13 <10% in proper clinical context 1.

2. Differentiate TTP Subtype

Test for anti-ADAMTS13 antibodies (inhibitors):

  • Antibodies present → Immune TTP (iTTP) - acquired autoimmune disease 1

    • Accounts for ~60% of cases with severe ADAMTS13 deficiency 4
    • May be associated with autoimmune manifestations (ANA positive in 71%, anti-dsDNA in some cases) 3
    • More common in Afro-Caribbean populations 3
  • Antibodies absent → Consider congenital TTP (cTTP) 1

    • Requires genetic testing for ADAMTS13 mutations (~250 known mutations)
    • Repeat antibody testing after therapy to confirm
    • Can present in neonates/children OR remain asymptomatic until adulthood 2

Important pitfall: Absence of detectable antibodies during acute episodes does NOT rule out iTTP—free antibodies may be undetectable due to ELISA limitations or accelerated clearance of antibody-ADAMTS13 complexes [1, @24@].

3. Exclude Secondary Causes

ADAMTS13 <5% is highly specific for idiopathic TTP. Studies show:

  • 0% of HUS patients have ADAMTS13 <5% 4
  • 0% of stem cell transplant-associated TMA have ADAMTS13 <5% 4
  • Only 2 of 17 patients with secondary TMA (cancer/chemotherapy) had ADAMTS13 <5% 4

If ADAMTS13 <5%, the diagnosis is almost certainly primary TTP (immune or congenital), not secondary TMA 5, 4, 6.

Prognostic Implications

Mortality Risk

  • Idiopathic TTP with ADAMTS13 <5%: 15% mortality 5
  • Patients with ADAMTS13 >25%: 59% mortality (likely secondary TMA with worse prognosis) 5

Treatment Response Predictors

Without inhibitors: Plasma exchange effectively raises ADAMTS13 levels and achieves complete clinical remission 5

With high-titer inhibitors (>5 units/mL):

  • ADAMTS13 levels fail to rise despite plasma exchange
  • Inhibitor titers remain elevated
  • 75% experience recurrent disease or death 5
  • Requires aggressive immunosuppression

Clinical Phenotype with ADAMTS13 <5%

Compared to patients with detectable ADAMTS13 activity, those with <5% have:

  • Lower platelet counts (median 12 vs 49.5 × 10⁹/L) 3
  • Less severe renal failure (GFR 78 vs 15.8 mL/min) 3
  • Lower risk of end-stage renal disease (3.2% vs 21.4%) 3
  • More autoimmune manifestations (polyarthritis, lupus-like features, positive autoantibodies) 3

Treatment Implications

Do not wait for ADAMTS13 results to initiate treatment—turnaround time can be several days, and TTP is immediately life-threatening 2.

For Immune TTP (iTTP):

  • Therapeutic plasma exchange (TPE) daily until platelet recovery
  • Corticosteroids (high-dose)
  • Rituximab for immunosuppression
  • Caplacizumab (anti-VWF nanobody) to accelerate recovery 1

For Congenital TTP (cTTP):

  • Recombinant ADAMTS13 is now the strong recommendation over fresh frozen plasma (2025 ISTH guidelines) 1
  • If recombinant ADAMTS13 unavailable, use fresh frozen plasma for prophylaxis
  • Lifelong replacement therapy required

Key Clinical Pearls

  1. ADAMTS13 <5% is ~60% sensitive for clinically diagnosed TTP but highly specific when present 4

  2. Severe ADAMTS13 deficiency alone may not be sufficient to cause acute TTP—environmental triggers or additional genetic factors may be required 2

  3. Schistocytes may be absent despite TTP diagnosis—do not rely solely on blood smear 2

  4. Use clinical scoring systems (French score or PLASMIC score) while awaiting ADAMTS13 results to assess likelihood of severe deficiency 1

  5. Monitor ADAMTS13 activity serially during treatment—failure to rise suggests high-titer inhibitors and poor prognosis 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.